Guidelines for referral and management of systemic lupus erythematosus in adults

Arthritis and Rheumatism

Volumn 42, Issue 9, 1999, Pages 1785-1796

  Gladman, Dafna D ^a   Urowitz, Murray B ^a   Esdaile, John M ^b   Hahn, Bevra H ^c   Klippel, John ^d   Lahita, Robert ^e   Liang, Matthew H ^f   Schur, Peter ^f   Petri, Michelle ^g   Wallace, Daniel ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^e ST VINCENT S HOSPITAL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; GASTROINTESTINAL HEMORRHAGE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIVER DISEASE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0013374274     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199909)42:9<1785::aid-anr1>3.0.co;2-%23     Document Type: Review

References (58)

1. Lahita RG, editor. Systemic lupus erythematosus. 3rd ed. San Diego: Academic Press; 1998.
2. Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 5th ed. Baltimore: Williams & Wilkins; 1997.
3. Schur P, editor. The clinical management of systemic lupus erythematosus. 2nd ed. Philadelphia: Lippincott; 1996.
4. Klippel J, editor. Primer on the rheumatic diseases, 11th ed. Atlanta: Arthritis Foundation; 1997.
5. Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby; 1998.
6. Koopman WJ, editor. Arthritis and allied conditions. 13th ed. Baltimore: Williams & Wilkins; 1997.
7. Kelley WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of rheumatology. 5th ed. Philadelphia: WB Saunders; 1997.
8. Maddison PJ, Isenberg DA, Woo P, Glass DN, editors. Oxford textbook of rheumatology. Oxford: Oxford University Press; 1997.
9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
11. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
12. Stoll T, Seifert B, Isenberg DA. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996;35:248-54.
13. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus: results from a single centre. I. Causes of death. J Rheumatol 1995;22:1259-64.
14. Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
15. Gladman DD. Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1996;8:430-7.
16. Boumpas DT, Fessler BJ, Austin HA III, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 2. Dermatologie and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995;123:42-53.
17. Esdaile JM, Joseph L, Mackenzie T, Kashgarian M, Hayslett JP. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 1994;21:2046-51.
18. Weinstein A, Bordwell B, Stone B, Tibbetts C, Rothfield NF. Antibodies to native DNA and serum complement (C3) levels: application to diagnosis and classification of systemic lupus erythematosus. Am J Med 1983;174:206-16.
19. Perez-Gutthann S, Petri M, Hochberg MC. Comparison of different methods of classifying patients with systemic lupus erythematosus. J Rheumatol 1991;18:1176-9.
20. Shiel WC Jr, Jason M. The diagnostic associations of patients with antinuclear antibodies referred to a community rheumatologist. J Rheumatol 1989;16:782-5.
21. Hahn BH. Mechanisms of disease: antibodies to DNA. N Engl J Med 1998;338:1359-68.
22. Calvo-Alén J, Bastian HM, Straaton KV, Burgard SL, Mikhail IS, Alarcón GS. Identification of patient subsets among those presumptively diagnosed with, referred, and/or followed up for systemic lupus erythematosus at a large tertiary care center. Arthritis Rheum 1995;38:1475-84.
23. Kalunian KC. Definition, classification, activity and damage indices. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 5th ed. Baltimore: Williams and Wilkins; 1997. p. 19-30.
24. Boumpas DT, Austin HA III, Fessier BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 1. Renal, neuropsychiatrie, cardiovascular, pulmonary and hematologic disease. Ann Intern Med 1995;122:940-50.
25. Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CGM. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990;33:634-43.
26. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus: a prospective cohort study. Arthritis Rheum 1991;34:937-44.
27. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters Dicke H, Hermans J, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995;345:1595-9.
28. Walz-Leblanc B, Gladman DD, Urowitz MB, Goodman PJ. Serologically active clinically quiescent SLE. J Rheumatol 1994; 21:2239-41.
29. Esdaile JM. Current role of renal biopsy in SLE. Baillieres Clin Rheumatol 1998;12:433-8.
30. Agus B, Nelson J, Kramer N, Mahal SS, Rosenstein ED. Acute central nervous system symptoms caused by ibuprofen in connective tissue disease. J Rheumatol 1990;17:1094-6.
31. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338:727-34.
32. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994;20:243-63.
33. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39: 1791-801.
34. Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 1997;24:654-62.
35. Watanabe Duffy KN, Duffy CM, Gladman DD. Infection and disease activity in SLE: a review of hospitalized patients. J Rheumatol 1991;18:1180-4.
36. Robbins L. Patient education. In: Klippel J, Weyand C, Wortmann R, editors. Primer on the rheumatic diseases. 11th ed. Atlanta: Arthritis Foundation; 1997. p. 416-8.
37. Wysenbeek AJ, Block DA, Fries JF. Prevalence and expression of photosensitivity in systemic lupus erythematosus. Ann Rheum Dis 1989;48:461-3.
38. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky SK, et al. Guidelines of care for cutaneous lupus erythematosus. J Am Acad Dermatol 1996;34:830-6.
39. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324:150-4.
40. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994;96:254-9.
41. Pollak VE, Pirani CL, Kark RM. Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis. J Lab Clin Med 1961;57:495-511.
42. Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone versus prednisone alone in the treatment of systemic lupus erythematosus: a report of a prospective, controlled trial in 24 patients. Ann Intern Med 1975;85:597-605.
43. Steinberg AD, Steinberg SC. Long term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50.
44. Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996;125:549-57.
45. Boumpas DT, Barez S, Klippel JH, Balow JE. Intermittent cyclophosphamide for the treatment of thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1990;112:674-7.
46. Boumpas DR, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE. Pulse cyclophosphamide for severe neuropsychiatrie lupus. QJM 1991;81:975-84.
47. Walz-Leblanc B, Urowitz MB, Gladman DD. Methotrexate in SLE. J Rheumatol 1994;21:836-8.
48. Wilson K, Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994;21:1674-7.
49. Jacobs P, Woods L. The comparison of gammaglobulin to steroids in treating adult immune thrombocytopenia: an interim analysis. Blut 1989;59:92-5.
50. West SG, Johnson SC. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1988;108:703-6.
51. Coon WW. Splenectomy for cytopenias associated with systemic lupus erythematosus. Am J Surg 1988;155:391-4.
52. Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994;4:551-8.
53. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992;326:1373-9.
54. Euler HH, Schwab UM, Schroeder JO, Hasford J. The Lupus Plasmapheresis Study Group; rationale and updated interim report. Artif Organs 1996;20:356-9.
55. Rund D, Schaap T, Gillis S. Intensive plasmapheresis for severe thrombotic thrombocytopenic purpura: long-term clinical outcome. J Clin Apheresis 1997;12:194-5.
56. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995;332:993-7.
57. Stone JH, Millward CL, Olson JL, Amend WJC, Criswell LA. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era. Arthritis Rheum 1998;41:678-86.
58. Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus: results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826-31.